Please login to the form below
influenza
This page shows the latest influenza news and features for those working in and with pharma, biotech and healthcare.
Externalities
Let’s briefly look at two such examples. Suppose, for a moment, that I get an annual influenza vaccine or flu shot.
Latest news
-
UK rations AZ’s paediatric flu vaccine after delivery delays
The delay means available stocks of the live, attenuated influenza vaccine (LAIV) will have to be reserved for vulnerable children with underlying medical conditions such as asthma, heart problems or cystic ... The company insists that it is
-
Roche scores another FDA approval for Xofluza
influenza-related complications – expanding its reach even further. . ... Its first indication was for acute, uncomplicated influenza in people aged 12 or older.
-
UK bans some drug exports to preserve NHS stocks
It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.
-
Declining childhood vaccination rates ring alarm bells in England
The figures also showed decreases in coverage of the 5-in-1 vaccine – which protects against diphtheria, tetanus, pertussis (whooping cough), polio and Haemophilus influenza type b (which can cause meningitis) –
-
Roche’s flu drug Xofluza scores phase 3 primary endpoint
Demonstrates efficacy as a preventative treatment. Roche has produced promising phase 3 data for its influenza drug Xofluza (baloxavir marboxil) as a preventative treatment for household members who are living with ... Xofluza was approved by the FDA
More from news
Approximately 16 fully matching, plus 188 partially matching documents found.
Latest Intelligence
-
Biotech profile: Tom Evans, CEO, Vaccitech.
What are the shortcomings of current influenza vaccines, and why are new products needed? ... The outcome measurement is to decrease the amount of laboratory-confirmed influenza illness.
-
Case study: Break the flu cycle
76% of delegates felt more confident in their ability to manage the influenza vaccination. ... influenza infection, particularly among the more at-risk group of 65 years and over.
-
Deal Watch February 2016
coli and influenza, and in toxicology applications. While Abbott already has a significant diagnostics presence with global sales in 2015 in this segment of $4.6bn, it forecasts that the acquisition
-
Another lost decade for research?
diseases that cause significant morbidity and mortality, such as influenza and malaria, but remain difficult to vaccinate against.
-
Pharma deals in June 2015
85. BioCryst Pharmaceuticals/ CSL. RAPIVAB (peramivir injection) for the treatment of influenza (marketed).
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest appointments
-
Germany's Ventaleon names biotech entrepeneur CEO
patients suffering from serious infections such as influenza to get better, faster.
-
Dr Michael Watson appointed as president of Valera
Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.
-
NDA Group appoints Bill Griffiths as general manager, UK
systems teams as well as a specialist influenza vaccines unit.
-
Takeda appoints head of vaccines development
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
-
MHRA chairman steps down
He was previously chair of the MHRA's Commission of Human Medicines and the Department of Health's Scientific Pandemic Influenza Committee.
More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Fake News is Bad for your Health
Epidemics of measles are occurring across Europe. Rates of vaccination for influenza, HPV, tetanus and polio have also declined.
-
To track disease, follow the money
The way that influenza spreads can be tracked by tools such as Flusurvey,(1) which produces rapidly-updated heatmaps of illness across the country.
-
Influenza
Agency: BASTARD. LONDON. Product: Self Promotion. Client: Self Promotion. Therapy area: Self Promotion. View the PMHub profile for: BASTARD. LONDON.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
Subscribe to our email news alerts
- AstraZeneca’s Calquence impresses in previously untreated CLL
- Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
- Sangamo steps up BioMarin chase with haemophilia gene therapy data
- PMEA 2019 Winners Gallery
- Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn
- J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data
- Frontera proud finalists for the 2020 PM Awards
- Brexit nears as Conservatives sweep to victory in election
- Roche’s Tecentriq combo scores in first-line melanoma
- House Democrats finally pass landmark drug pricing bill
- UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
- FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- The 2019 CPhI Pharma Index Report
- Examining this year’s industry performance...
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Quick links
Infographics
